HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Laboratory studies suggest that mechanisms of resistance to tyrosine kinase inhibitor therapy differ between the specific subtypes of HER2-positive breast cancer.

Source: CancerNetwork - April 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news